November 18, 2026 · Annals of surgical oncology · DOI: 10.1245/s10434-026-20917-5

Residual Cervical Risk After Neoadjuvant Immunochemotherapy: A Target-trial Emulation of Elective Neck Dissection Versus Omission in cT3/4aN0 Oral Squamous Cell Carcinoma.

Listen to this summary

This retrospective target-trial emulation of 421 patients with cT3/4aN0 oral squamous cell carcinoma downstaged to ycN0 after neoadjuvant immunochemotherapy asked whether omitting elective neck dissection (END) increases 3-year cervical recurrence. Omission was associated with roughly double the recurrence hazard (subdistribution HR 2.06, 95% CI 1.03-4.12), with weighted 3-year incidence of 14.8% versus 7.2%, although the absolute risk difference CI included zero. Because 13.5% of dissected patients had occult nodal disease, the authors conclude that radiologic nodal negativity does not exclude residual disease and that routine END omission is not supported.

Zhengquan Zhou

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play